Phase II Study of Sequential Administration of Doxorubicin, Paclitaxel, and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven primary stage III or IV or recurrent endometrial cancer

- Bidimensionally measurable disease by x-ray, CT scan, MRI scan, or physical exam

- Sole site may be within a previously irradiated area if documented disease
progression since prior radiotherapy

PATIENT CHARACTERISTICS:

Age:

- Adult

Performance status:

- Karnofsky 70-100%

Life expectancy:

- At least 12 weeks

Hematopoietic:

- Absolute neutrophil count greater than 1,000/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin, SGOT, and alkaline phosphatase no greater than 1.5 times normal

Renal:

- Creatinine no greater than 1.8 mg/dL

Cardiovascular:

- Left ventricular ejection fraction at least 50%

Other:

- No active uncontrolled infection

- No greater than grade II neuropathy

- No other active malignancy

- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior doxorubicin

- Greater than 6 months since prior paclitaxel, carboplatin, or other platinum
compounds

Endocrine therapy:

- Not specified

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy and recovered

Surgery:

- Not specified